pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Monoclonal Antibody · news · pharmadog
← back to Monoclonal Antibody
News · Monoclonal Antibody
785
stories
25d
ESMO 2026: Amgen’s Imdelltra slashes death risk by nearly 60% in small cell lung cancer
biospace
25d
#ESMO26: SystImmune/BMS and Hengrui detail data in EGFR-mutant lung cancer
endpoints
25d
Another autoimmune CAR-T death; Treasury zeroes in on China deals
biopharma dive
26d
Genmab’s ADC beats survival expectations in Phase 3 ovarian cancer trial
biospace
26d
BioNTech, DualityBio ponder next steps for HER2 ADC after 'modest' breast cancer results
endpoints
26d
Novel protein and peptide therapeutics
biopharma dive
26d
BioNTech sees ‘limited’ benefit to ADC after phase 3 reveals modest efficacy, ILD cases
fiercebiotech
26d
#ESMO26: Akeso details ivonescimab's biliary cancer success, drawing Keytruda comparisons
endpoints
27d
ESMO: BMS’ Massacesi hails ‘very promising’ data for BioNTech-partnered PD-L1xVEGF-A drug
fiercebiotech
27d
ESMO: Why Incyte sees itself ‘neck and neck’ with RevMed in KRAS G12D pancreatic cancer race
fiercebiotech
27d
#ESMO26: AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere; Nubeqa targets earlier prostate cancer
endpoints
28d
ESMO: AstraZeneca exec insists phase 3 ADC data ‘robust’ enough for regulators despite PFS miss
fiercebiotech
28d
‘It is what it is’: Merck exec unruffled by ‘unfortunate’ leak of ESMO cancer vaccine data
fiercebiotech
28d
Opinion: It took me 13 years to be diagnosed with MS. Christina Applegate’s misdiagnosis doesn’t surprise me
stat
28d
Lycia's $318M IPO; Merck sac-TMT trial stopped early
endpoints
28d
ESMO 2026: Marengo's bispecific antibody shrinks 8 tumor types in Phase 2
biospace
29d
Roche bets up to $813M on Zymeworks’ lung cancer trispecific T cell engager
biospace
29d
Gilead to pay $1.3B upfront for PepStar’s oral IL-23 challenger to J&J’s Icotyde
fiercebiotech
29d
Bolt makes inflammation play with Prana reverse merger, $120M financing
fiercebiotech
29d
ESMO: Takeda’s $1.2B bet on Innovent ‘absolutely’ pays off with details of ADC’s phase 3 win
fiercebiotech
29d
Roche pays Zymeworks $55M for trispecific challenger to Amgen’s Imdelltra
fiercebiotech
29d
Protein degrader specialist Lycia prices $318M IPO
biopharma dive
29d
Treasury sweeps biotech into proposed COINS Act restrictions, but spares Big Pharma’s China licensing deals
fiercebiotech
29d
AbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectations
biospace
29d
Chutes & Ladders—Troubled CSL enlists GSK vet Deborah Waterhouse to lead
fiercebiotech
29d
GSK, Ionis hepatitis B functional cure breaks open market for followers
biospace
29d
Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T asset
biospace
Oct 22, 26
AbbVie scratches out phase 3 hidradenitis suppurativa win but falls short of expectations
fiercebiotech
Oct 22, 26
Celltrion picks up another Kaigene autoimmune antibody for up to $580.5M
fiercebiotech
Oct 22, 26
Menarini's Stemline picks up Georgiamune preclinical cancer immunotherapy in $1.1B deal
fiercebiotech
← prev
page 6 of 27
next →